Friday, December 19, 2014

New drugs on the market

From Momenta:
"Necuparanib (formerly M402) is a novel, rationally designed, oncology drug candidate under investigation in metastatic pancreatic cancer.  The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. Necuparanib, which is derived from unfractionated heparin, has been engineered to have significantly reduced anticoagulant activity while preserving the relevant antitumor properties of heparin. Necuparanib binds to multiple growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis."

JUST REMEMBER HEPARAN SURFACE IF THE COVER OF ESTROGEN RECEPTORS AND MANY OTHER RECEPTORS  HUMMMM! CAN THIS PRODUCT WORK IN ER POSITIVE TUMOR?

" Twelve patients treated with necuparanib plus Abraxane and Gemzar completed the first 28-day treatment cycle. They had at least one follow up CT scan and were considered eligible for evaluating radiographic response. Out of them, seven patients showed a RECIST partial response and four patients reported stable disease.

Moreover, 11 out of the 12 patients showed a more than 50% decrease in CA19.9 levels (a predictive biomarker for long-term outcome and treatment response in pancreatic cancer) from baseline. The remaining patient achieved a more than 20% decrease from baseline. Overall, disease control was achieved in 92% of these 12 patients."
Post a Comment